Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.
about
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategiesSome aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversyNew strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practiceThe clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes.Prognostic significance of a comprehensive histologic evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients.Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO studyPresence of new mutations in the TP53 gene in patients with low-risk myelodysplastic syndrome: two case reportsAtypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.The search for better prognostic models in myelodysplastic syndromesAllogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis.Role and timing of hematopoietic cell transplantation for myelodysplastic syndrome.Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.Revised international prognostic scoring system for myelodysplastic syndromes.Hypomethylating agents and other novel strategies in myelodysplastic syndromes.Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy.Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET studyDiagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.The genetic basis of myelodysplasia and its clinical relevanceDiagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.Standards and impact of hematopathology in myelodysplastic syndromes (MDS).The bone marrow stroma in hematological neoplasms--a guilty bystander.Advances in the prognostication and management of advanced MDS in children.Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia.When to transplant MDS, and what to do when transplant fails.Myelodysplastic syndromes: toward a risk-adapted treatment approach.Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.I walk the line: how to tell MDS from other bone marrow failure conditions.The myelodysplastic syndromes: the era of understanding.Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes.Importance of classical morphology in the diagnosis of myelodysplastic syndrome.Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions.Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia.p53 protein expression in patients with myelodysplasia treated with allogeneic bone marrow transplantation.Rethinking the usefulness of bone marrow biopsy on treatment decision in CLL patients at diagnosis.Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes.Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.
P2860
Q26744113-139528E9-DE37-4CCF-8F4B-75E227B66FA5Q27010653-82B0E96D-8D91-4B89-B975-6714061F28A4Q27016511-FC4690E9-3E79-4B75-A7FD-36D36145436EQ33407572-B5DD4671-7498-46A2-B47A-19B4F41B30A2Q33443649-AD1659CB-FBE0-4D1D-9B5F-78E4D73B4FA0Q33707461-603542BD-8EF0-4FC5-815E-B593A636F287Q33710464-DD6D4278-90E0-4C1D-B9FE-F485966E7083Q33794297-ACA708A5-5D67-4DDB-875B-8204D8DBDF6FQ34049017-8E59B177-8F83-4F70-A15D-81B885FDA482Q34386812-9A5C4016-5130-45FC-A658-09E6C830E9C4Q34543049-9ED1E139-64BB-42C0-8550-76E3D95D25CBQ34549306-6FDBAFA0-202F-4AC8-9DC3-79A790C44035Q34612644-8002B9A7-B64C-4D27-B43B-12B3993446E7Q34639717-08E0E467-F74A-48A2-85F0-DDCCA859EAB4Q34667051-2421CE20-1C6E-452A-BB72-E1B3B0B173C2Q35265820-AC91FD4E-ADDE-4DA1-A755-494929527DCDQ35414429-2F4F923A-FBE0-4737-82CE-74599EF9515FQ36133023-7F14B0C4-F2B4-4E1C-8866-F29F8CF82F52Q37263146-B2776B5F-F0CE-40E2-87FF-B04F1DB4CDB8Q37390236-543C0915-F1B6-4B43-872E-645801549B37Q37679175-C0463AE7-19C5-4465-9452-5B0F92C8BAC8Q37772200-E94E452B-9CE9-4EE3-B526-A0172FE77142Q37840934-1C35C8AA-A664-47CD-8C19-F8D606BD0E40Q37859253-A01F60C6-310B-45A0-8A6D-BE7890C1F6CDQ37873542-60556094-36BB-45B8-9FC2-C2F62F506FF5Q37889846-5C04203D-9D9D-4479-BD0B-5504768E2811Q38148983-CC433FA3-078B-41D9-9B23-11104A747380Q38149315-20E96EF9-5010-428B-9AD1-330F290C4163Q38220788-C69B21E1-9FD9-41E6-833F-D0C63E3D79A2Q38235622-FE21A4E9-6791-4898-B4FF-F3A0CCB43813Q38245878-ADE75ED9-BE65-469B-B442-57EFBF7AD1CCQ38323957-714C8D23-2B1E-404C-B4E7-276724959F30Q38471249-AE7A321F-4157-4A21-8F89-2E6497E682E0Q38678113-A9B0C479-39D3-4929-951C-F55ED3E4AF12Q38739162-FB979FDA-5FA9-4AE0-AA5C-9ECE09E95F16Q38739506-35FDE8E6-F43A-42D0-95AE-F5C3919365A7Q38823803-908C7D37-05E0-431B-A05A-EA8B8CD0DAF9Q38908087-6BF3287B-98E3-45F0-B070-FCDAF981AC8CQ39092515-0E6B9F8D-059F-4B26-82D9-D9DC5778BD16Q39155501-4F85A5AA-E949-4768-92A1-443CDFD31B2E
P2860
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Clinical relevance of bone mar ...... ary myelodysplastic syndromes.
@en
Clinical relevance of bone mar ...... ary myelodysplastic syndromes.
@nl
type
label
Clinical relevance of bone mar ...... ary myelodysplastic syndromes.
@en
Clinical relevance of bone mar ...... ary myelodysplastic syndromes.
@nl
prefLabel
Clinical relevance of bone mar ...... ary myelodysplastic syndromes.
@en
Clinical relevance of bone mar ...... ary myelodysplastic syndromes.
@nl
P2093
P356
P1476
Clinical relevance of bone mar ...... ary myelodysplastic syndromes.
@en
P2093
Alessandro Castello
Cristiana Pascutto
Emanuela Boveri
Erica Travaglino
Luca Malcovati
Mario Cazzola
Mario Lazzarino
Matteo Giovanni Della Porta
Rosangela Invernizzi
Umberto Magrini
P304
P356
10.1200/JCO.2008.18.2246
P407
P577
2008-12-22T00:00:00Z